Literature DB >> 9086435

VH gene expression in CD5 positive and CD5 negative B cell chronic lymphoid malignancies.

K Maloum1, O Pritsch, C Magnac, F Davi, J L Binet, H Merle-Beral, G Dighiero.   

Abstract

In this review, we report analyses of VH genes in mature B cell malignancies generally or occasionally bearing CD5 antigen such as B CLL, MCL, SLVL and PLL. In the majority of cases, B CLL and MCL use VH genes in germline configuration. However in some cases a higher rate of random mutations is observed. These differences are not related to CD5 expression but are accounted by Ig phenotype, since less mutations are observed in CLL cases expressing membrane mu delta, when compared to forms exclusively expressing membrane mu. PLL and SLVL cases display mutated V genes independently of CD5 expression. Although there is some evidence that CD5+ B cells constitute a separate lineage, the possibility that CD5 constitutes an activation marker cannot be ruled out. Indeed, CD5- B cells can be induced to differentiate into CD5+ B cells and VH gene analyses showed no significative differences between CD5+ and CD5- B cell lymphoproliferative disorders. In this review we have tried to examine B cell chronic malignancies on the basis of phenotype and VH gene usage. Thus we propose a tentative classification where these disorders are allocated according to these characteristics.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9086435     DOI: 10.3109/10428199709055582

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Clinical and phenotypic features of CD5-negative B cell chronic lymphoproliferative disease resembling chronic lymphocytic leukemia.

Authors:  Ciro Romano; Ausilia Sellitto; Federico Chiurazzi; Luigia Simeone; Umberto De Fanis; Maddalena Raia; Luigi Del Vecchio; Giacomo Lucivero
Journal:  Int J Hematol       Date:  2014-11-29       Impact factor: 2.490

2.  Clinical and Laboratory Features of CD5-Negative Chronic Lymphocytic Leukemia.

Authors:  Cengiz Demir; Erdal Kara; Ömer Ekinci; Senar Ebinç
Journal:  Med Sci Monit       Date:  2017-05-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.